{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-325299","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.112687+00:00","generated_at":"2026-06-28T09:56:07.886468+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease","bullets":["ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.","The Phase 1 INTERCEPT-AD trial design is detailed in the presentation posted on November 10, 2021.","The presentation is available on Acumen's website and was furnished to the SEC as Exhibit 99.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-325299","json":"https://secwatch.observer/filing/0001193125-21-325299.json","markdown":"https://secwatch.observer/filing/0001193125-21-325299.md","text":"https://secwatch.observer/filing/0001193125-21-325299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/0001193125-21-325299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/d234985d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:56:07.886468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}